Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Incidence, Predictors, Consequences, Prevention, and Treatment of Coronary Occlusion During TAVR: Practical Clinical Guidelines

Presenter: Ariel Finkelstein

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NO: The Data Are Weak and the Costs Are Prohibitive!

Presenter: John K. Forrest

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

YES: Review of ALL the Data and Common Sense Tell the Story!

Presenter: Axel Linke

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Presenter: Eberhard Grube, Tamim Nazif

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cedars-Sinai Medical Center (USA)

Presenter: Tarun Chakravarty

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Erasmus University (The Netherlands)

Presenter: Nicolas M. Van Mieghem

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Ulm University (Germany)

Presenter: Julia Seeger

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Presenter: Eberhard Grube, Tamim Nazif, Hemal Gada

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Presenter: Eberhard Grube, Tamim Nazif, Alexandra J. Lansky

June 21, 2018

Advertisement

Incidence, Predictors, Consequences, Prevention, and Treatment of Coronary Occlusion During TAVR: Practical Clinical Guidelines

NO: The Data Are Weak and the Costs Are Prohibitive!

YES: Review of ALL the Data and Common Sense Tell the Story!

Keystone TRIGUARD Cerebral Embolic Protection During TAVR: New Generation Devices and the Status of Ongoing Clinical Trials

Cedars-Sinai Medical Center (USA)

Erasmus University (The Netherlands)

Ulm University (Germany)

Cost-effectiveness of Cerebral Protection During TAVR: Can We Justify Systematic Use?

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Strokes After TAVR (and SAVR): Incidence in the "Modern Era" and Key Messages From NeuroARC

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content